Journal article
A tailored approach to horizon scanning for cancer medicines
JA Soon, YH To, M Alexander, K Trapani, PA Ascierto, S Athan, MP Brown, M Burge, A Haydon, B Hughes, M Itchins, T John, S Kao, M Koopman, BT Li, GV Long, JM Loree, B Markman, TM Meniawy, AM Menzies Show all
Journal of Cancer Policy | Elsevier | Published : 2023
Abstract
Background: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis weighting and Delphi rounds. As secondary objectives, we aimed to identify new medicines in melanoma, non-small cell lung cancer and colorectal cancer most likely to impact the Australian government's pharmaceutical budget by 2025 and to compare clinician and consumer priorities in cancer medicine reimbursement. Method: Three cancer-specific clinician panels (total n = 27) and a consumer panel (n = 7) were formed. Six prioritisation criteria were developed with consumer..
View full abstractGrants
Awarded by University of Melbourne
Funding Acknowledgements
This research was part of the Predicting the population health economic Impact of current and new CAncer Therapies (PRIMCAT) study which is funded by the Medical Research Future Fund, Preventative and Public Health THSCOR 2019 (Targeted Health Systems and Community Organisation Research), grant number 2020/MRF1199701. All published materials are the responsibility of the research team and do not reflect the views of the Commonwealth.